Clinical trial
Efficacy and Safety of a Long Acting Anti-Psychotic Versus Placebo in Patients…
NCT00101634 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry · Completed
Key facts
| NCT number | NCT00101634 |
|---|---|
| Title | Efficacy and Safety of a Long Acting Anti-Psychotic Versus Placebo in Patients With Schizophrenia |
| Official title | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-response Study to Evaluate the Efficacy and Safety of 3 Fixed Doses (25 mg eq, 50 mg eq, and 100 mg eq) of Paliperidone Palmitate in Patients With Schizophrenia |
| Lead sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Schizophrenia |
| Intervention type | Drug |
| Interventions | Paliperidone palmitate |
| Enrollment | 518 |
| Start date | Dec 1, 2004 |
| Completion | Mar 1, 2006 |
| First posted | Jan 13, 2005 |
| Last update posted | Jun 8, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: